Cellosaurus logo
expasy logo

Cellosaurus UWB1.289 (CVCL_B079)

[Text version]
Cell line name UWB1.289
Synonyms UWB1-289; UWB1289
Accession CVCL_B079
Resource Identification Initiative To cite this cell line use: UWB1.289 (RRID:CVCL_B079)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: OCCP ovarian cancer cell line panel.
Population: Caucasian.
Doubling time: 15.3 hours (PubMed=17259345); ~53 hours (ATCC=CRL-2945).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: HLA class I peptidome analysis by proteomics.
Omics: Transcriptome analysis by microarray.
Sequence variations
  • Gene deletion; HGNC; 1100; BRCA1; Zygosity=Heterozygous (PubMed=17259345).
  • Mutation; HGNC; 1100; BRCA1; Simple; p.Asp825Glufs*21 (c.2475delC); ClinVar=VCV000037472; Zygosity=Heterozygous (PubMed=17259345).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.18
Native American0
East Asian, North0.95
East Asian, South0
South Asian1.35
European, North70.57
European, South26.96
Disease BRCA1-associated hereditary breast and ovarian cancer syndrome (NCIt: C36100)
Hereditary breast and ovarian cancer syndrome (ORDO: Orphanet_145)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_B078 (UWB1.289+BRCA1)
Sex of cell Female
Age at sampling 56Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DepMap; PubMed=25230021

Markers:
AmelogeninX
CSF1PO11
D3S135814,15
D5S81813
D7S8207,10
D8S117911,12 (DepMap)
12 (PubMed=25230021)
D13S3179
D16S53912
D18S5119
D21S1128,31
FGA22
Penta D10
Penta E8
TH019
TPOX9,11
vWA16,19

Run an STR similarity search on this cell line
Publications

PubMed=17259345; DOI=10.1158/1541-7786.MCR-06-0234
DelloRusso C., Welcsh P.L., Wang W.-X., Garcia R.L., King M.-C., Swisher E.M.
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
Mol. Cancer Res. 5:35-45(2007)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29242379; DOI=10.1074/mcp.TIR117.000383
Chong C., Marino F., Pak H., Racle J., Daniel R.T., Muller M., Gfeller D., Coukos G., Bassani-Sternberg M.
High-throughput and sensitive immunopeptidomics platform reveals profound interferon gamma-mediated remodeling of the human leukocyte antigen (HLA) ligandome.
Mol. Cell. Proteomics 17:533-548(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2945
Cell line databases/resources cancercelllines; CVCL_B079
Cell_Model_Passport; SIDM00815
Cosmic-CLP; 1480374
DepMap; ACH-001418
Lonza; 1665
Anatomy/cell type resources BTO; BTO:0006253
Biological sample resources BioSample; SAMN03471702
CRISP screens repositories BioGRID_ORCS_Cell_line; 1041
Chemistry resources GDSC; 1480374
PharmacoDB; UWB1_289_1650_2019
Encyclopedic resources Wikidata; Q54992390
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM711714
GEO; GSM1291155
GEO; GSM1670568
Proteomic databases PRIDE; PXD006939
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation06-Jun-2012
Last entry update30-Jan-2024
Version number28